Compare WING & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | MMED |
|---|---|---|
| Founded | 1994 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2015 | 2026 |
| Metric | WING | MMED |
|---|---|---|
| Price | $156.79 | $11.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 27 | 10 |
| Target Price | ★ $295.92 | $22.56 |
| AVG Volume (30 Days) | ★ 1.4M | 577.4K |
| Earning Date | 04-29-2026 | 06-03-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $17.20 | $15.99 |
| Revenue Next Year | $15.86 | $10.00 |
| P/E Ratio | $146.46 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $116.35 | $10.65 |
| 52 Week High | $388.14 | $17.86 |
| Indicator | WING | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 48.16 |
| Support Level | $142.24 | $10.65 |
| Resistance Level | $285.21 | $12.19 |
| Average True Range (ATR) | 8.49 | 0.74 |
| MACD | 5.16 | 0.15 |
| Stochastic Oscillator | 91.69 | 76.62 |
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.